RE: Merck & Revolution Medicines ($32B) vs. Avacta: Why the pre|CISION Platform is the Real Tier-1 Prize12 Jan 2026 15:47
The Tempus “partnership “ is of no direct financial use to Avacta although obviously its huge database and analysis tools are key in Avacta establishing the best profiles for target patients. As far as I can gather the database is historical and anonymous and in no way provides a list of patients for future trials. As an aside, based on AVA6000 progress (and CC’s explanation of what is involved) IMHO 6103 dosing will not start in 1Q26. I will be delighted if it does.
Nice verse, Tempus does not directly benefit financially in Avacta’s success other than them continuing to be a lucrative customer.